PAG
ABCL icon

Private Advisor Group’s AbCellera Biologics ABCL Stock Holding History

Private Advisor Group’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$82K Buy
+10,450
New +$51.1K ﹤0.01% 2450

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Private Advisor Group's ABCL Position: Q2 2026 in Review

Private Advisor Group opened a new position in AbCellera Biologics (ABCL) in Q2 2026: 10,450 shares worth $82K. The stake represents ﹤0.01% of the portfolio and ranks #2450 among its holdings.

151 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

  • Private Advisor Group held 10,450 shares of AbCellera Biologics worth $82K as of Q2 2026.
  • AbCellera Biologics was a new Private Advisor Group position in Q2 2026.
  • AbCellera Biologics made up ﹤0.01% of Private Advisor Group's portfolio in Q2 2026, its #2450 holding.
  • 151 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on Private Advisor Group's 13F filing for Q2 2026, filed 27 Jul 2026.